An announcement from Cellectis SA ( (CLLS) ) is now available.
On February 24, 2025, Cellectis announced a novel ‘Smart CAR T’ strategy aimed at enhancing the efficacy of CAR T-cell therapies against solid tumors, presented at the AACR-IO conference. The strategy involves engineering CAR T cells to express an IL-2 variant that boosts anti-tumor activity while minimizing systemic toxicity, marking a significant advancement in the safety and effectiveness of CAR T therapies, potentially improving outcomes for cancer patients.
More about Cellectis SA
Cellectis is a clinical-stage biotechnology company that utilizes its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company focuses on an allogeneic approach for CAR T immunotherapies in oncology, aiming to provide off-the-shelf, ready-to-use gene-edited CAR T-cells for cancer treatment. With headquarters in Paris, France, and locations in New York and Raleigh, NC, Cellectis is listed on Nasdaq and Euronext Growth.
YTD Price Performance: -15.47%
Average Trading Volume: 147,405
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $113.9M
For a thorough assessment of CLLS stock, go to TipRanks’ Stock Analysis page.